Biology of bipolar disorder
From Wikipedia, the free encyclopedia
Bipolar disorder is a mood disorder characterized by alternating periods of manic (elevated) and depressed mood. While the exact cause and mechanism of bipolar disorder remains unknown, ongoing research focuses on uncovering its biological origins. Although no single gene has been identified as the cause, numerous genes are associated with an increased risk of developing the disorder. Gene-environment interactions are also believed to play a role in predisposing individuals to bipolar disorder.
Neuroimaging and postmortem studies have identified abnormalities in several brain regions, with the ventral prefrontal cortex and amygdala being most frequently implicated. Dysfunction within the emotional circuits of these regions has been hypothesized as a potential mechanism underlying bipolar disorder.[2] Additionally, evidence points to abnormalities in neurotransmission, intracellular signaling, and cellular functioning as contributing factors.[3]
Research into bipolar disorder, particularly neuroimaging studies, faces challenges such as confounding effects of medication, comorbid conditions, and small sample sizes, which may result in underpowered studies and significant heterogeneity in findings.[4]
Genetic
The aetiology of bipolar disorder is unknown. The overall heritability of bipolar is estimated at 79%-93%, and first-degree relatives of bipolar probands have a relative risk of developing bipolar disorder of around 7–10. While the heritability is very high, no specific genes have been conclusively associated with bipolar disorder, and a number of hypotheses have been posited to explain this fact. "The polygenic common rare variant" hypothesis suggests that a large number of risk-conferring genes are carried in a population, and that a disease manifests when a person has a sufficient number of these genes. The "multiple rare variant" model suggests that multiple genes that are rare in the population are capable of causing a disease, and that carrying one or a few can lead to disease.[6] The familial transmission of mania and depression are largely independent of each other. This raises the possibility that bipolar is actually two biologically distinct but highly comorbid conditions.[7]
A number of genome wide associations have been reported, including CACNA1C[8] and ODZ4, and TRANK1.[9][10][11][12][13] Less consistently reported loci include ANK3 and NCAN, ITIH1, ITIH3 and NEK4. Significant overlaps with schizophrenia have been reported at CACNA1C, ITIH, ANK3, and ZNF804A. This overlap is congruent with the observation that relatives of probands with schizophrenia are at higher risk for bipolar disorder and vice versa.
In light of associations between bipolar and circadian abnormalities (such as decreased need for sleep and increased sleep latency), polymorphisms in the CLOCK gene have been tested for association, although findings have been inconsistent,[6] and one meta analysis has reported no association with either bipolar or major depressive disorder.[14] Other circadian genes associated with bipolar at relaxed significance thresholds include ARTNL, RORB, and DEC1.[15] One meta analysis reported a significant association of the short allele of the serotonin transporter, although the study was specific to European populations.[16] Two polymorphisms in the tryptophan hydroxylase 2 gene have been associated with bipolar disorder.[17] NFIA has been linked with seasonal patterns of mania.[18]
One particular SNP located on CACNA1C that confers risk for bipolar disorder is also associated with elevated CACNA1C mRNA expression in the prefrontal cortex, and increased calcium channel expression in neurons made from patient induced pluripotent stem cells.[19]
No significant association exists for the BDNF Val66Met allele and bipolar disorder, except possibly in a subgroup of bipolar II cases,[20] and suicide.[21]
Due to the inconsistent findings in GWAS, multiple studies have undertaken the approach of analyzing SNPs in biological pathways. Signaling pathways traditionally associated with bipolar disorder that have been supported by these studies include CRH signaling, cardiac β-adrenergic signaling, phospholipase C signaling, glutamate receptor signaling,[22] cardiac hypertrophy signaling, Wnt signaling, notch signaling,[23] and endothelin 1 signaling. Of the 16 genes identified in these pathways, three were found to be dysregulated in the dorsolateral prefrontal cortex portion of the brain in post-mortem studies, CACNA1C, GNG2, and ITPR2.[24]
Advanced paternal age has been linked to a somewhat increased chance of bipolar disorder in offspring, consistent with a hypothesis of increased new genetic mutations.[25]
A meta-analysis was performed to determine the association between bipolar disorder and oxidative DNA damage measured by 8-hydroxy-2'-8-deoxyguanosine (8-OHdG) or 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG).[26] Levels of 8-OHdG and 8-oxodG are widely used as measures of oxidative stress in mental illnesses.[26] It was determined from this meta-analysis that oxidative DNA damage was significantly increased in bipolar disorder.
Environmental
Manic episodes can be produced by sleep deprivation in around 30% of people with bipolar. While not all people with bipolar demonstrate seasonality of affective symptoms, it is a consistently reported feature that supports theories of circadian dysfunction in bipolars.[27]
Risk factors for bipolar include obstetric complications, abuse, drug use, and major life stressors.[28]
The "kindling model" of mood disorders suggests that major environmental stressors trigger initial mood episodes, but as mood episodes occur, weaker and weaker triggers can precipitate an affective episode. This model was initially created for epilepsy, to explain why weaker and weaker electrical stimulation was necessary to elicit a seizure as the disease progressed. While parallels have been drawn between bipolar disorder and epilepsy, supporting the kindling hypothesis,[29] this model is generally not supported by studies directly assessing it in bipolar subjects.[27]
Neurological disorders
Mania occurs secondary to neurological conditions between a rate of 2% to 30%. Mania is most commonly seen in right sided lesions, lesions that disconnect the prefrontal cortex, or excitatory lesions in the left hemisphere.[30]
Diseases associated with "secondary mania" include Cushing's disease, dementia, delirium, meningitis, hyperparathyroidism, hypoparathyroidism, thyrotoxicosis, multiple sclerosis, Huntington's disease, epilepsy, neurosyphillis, HIV dementia, uremia, as well as traumatic brain injury and vitamin B12 deficiency.[31]
Pathophysiology
Neurobiological and neuroanatomical models
The main loci of neuroimaging and neuropathological findings in bipolar have been proposed to constitute dysfunction in a "visceromotor" network, composed of the medial prefrontal cortex (mPFC), anterior cingulate cortex (ACC), orbitofrontal cortex (OFC), hippocampus, amygdala, hypothalamus, striatum and thalamus.[32]
A model of functional neuroanatomy produced by a workgroup led by Stephen M. Strakowski concluded that bipolar was characterized by reduced connectivity, due to abnormal pruning or development, in the prefrontal-striatal-pallidal-thalamic-limbic network leading to dysregulated emotional responses. This model was supported by a number of common neuroimaging findings. Dysregulation of limbic structures is evinced by the fact that hyperactivity in the amygdala in response to facial stimuli has been consistently reported in mania.[33] While amygdala hyperactivity is not a uniform finding, a number of methodological challenges could explain discrepancies. As most studies utilize fMRI to measure blood-oxygen-level dependent signal, excess baseline activity could result in null findings due to subtraction analysis. Furthermore, heterogenous study design could mask consistent hyperactivity to specific stimuli. Regardless of directionality of amygdala abnormalities, as the amygdala plays a central role in emotional systems, these findings support dysfunctional emotional circuits in bipolar. A general reduction in ventrolateral prefrontal cortex activity is observed in bipolar, and is lateralized with regard to mood (i.e., left-depression, right-mania), and may underlie amygdala abnormalities. The dorsal ACC is commonly under-activated in bipolar, and is generally implicated in cognitive functions, while the ventral ACC is hyperactive and implicated in emotional functions. Combined, these abnormalities support the prefrontal-striatal-pallidial-thalamic limbic network underlying dysfunction in emotional regulation in bipolar disorder.[34] Strakowski, along with DelBello and Adler have put forward a model of "anterior limbic" dysfunction in bipolar disorder in a number of papers.[35][36][37][38][39]
Green et al. 2007 suggested a model of bipolar disorder based on the convergence of cognitive and emotional processing on certain structures. For example, the dACC and sgACC were cognitively associated with impairment of inhibition of emotional responses and self monitoring, which could translate to emotional stimuli having excessive impact on mood. Deficits in working memory associated with abnormal dlPFC function could also translate to impaired ability to represent emotional stimuli, and therefore the impaired ability to reappraise emotional stimuli. Dysfunction in the amygdala and striatum has been associated with attentional biases, and may represent a bottom up mechanism of dysfunctional emotional processing.[40]
Blond et al. proposed a model centered on dysfunction in an "amygdala-anterior paralimbic" system. This model was based on the consistent functional and structural abnormalities in the ventral prefrontal cortex and amygdala. The model also proposes a developmental component of bipolar disorder, wherein limbic abnormalities are present early on, but rostral prefrontal abnormalities develop later in the course. The importance of limbic dysfunction early in development is highlighted by the observation that amygdala lesions early in adulthood produce emotional abnormalities that are not present in people who develop amygdala damage in adulthood.[41]
Lateralized seizure sequelae similar to bipolar has been reported in people with mesial temporal lobe seizures, and provides support for kindling hypotheses about bipolar.[42] This observation led to the first experiments with anticonvulsants in bipolar, which are effective in stabilizing mood. Studies reporting reduced markers of inhibitory interneurons post-mortem link the analogy with epilepsy to a possible reduction in inhibitory activity in emotional circuits.[41] Overlap with epilepsy extends to include abnormalities in intracellular signaling, biochemistry in the hippocampus and prefrontal cortex, and structure and function of the amygdala.[43]
The phenomenology and neuroanatomy of mania secondary to neurological disorders is consistent with findings in primary mania and bipolar disorder. While the diversity of lesions and difficulty in ruling out premorbid psychiatric conditions limit the conclusions that can be drawn, a number of findings are fairly consistent. Structurally, secondary mania is associated with destructive lesions that tend to occur in the right hemisphere, particularly the frontal cortex, mesial temporal lobe and basal ganglia. Functionally hyperactivity in the left basal ganglia and subcortical structures, and hypoactivity in the right ventral prefrontal and basotemporal cortex have been reported in cases of secondary mania. The destruction of right hemisphere or frontal areas is hypothesized to lead to a shift to excessive left sided or subcortical reward processing.[30]
John O. Brooks III put forward a model of bipolar disorder involving dysregulation of a circuit called the "corticolimbic system". The model was based on more or less consistent observations of reduced activity in the medial orbitofrontal cortex, vlPFC, and dlPFC, as well as the more or less consistent observations of increased activity in the amygdala, parahippocampal gyrus, cerebellar vermis, anterior temporal cortex, sgACC, and ACC. This pattern of abnormal activity was suggested to contribute to disrupted cognitive and affective processes in bipolar disorder.[44]
Neurocognition
During acute mood episodes, people with bipolar demonstrate mood congruent processing biases. Depressed patients are quicker to react to negatively valenced stimuli, while manic patients are quicker to react to positively valenced stimuli.[45] Acute mood episodes are also associated with congruent abnormalities during decision making tasks. Depressed bipolar is associated with conservative responding, while manic bipolar is associated with liberal responses. Both depression and mania are associated with similar and broad cognitive impairments, including on tests of attention, processing speed, working memory, executive functions, and reaction time.[46]
Clinically, mania is characterized by spending sprees, poor judgement, and inappropriate speech and behavior. Congruent with this, mania is associated impulsivity on Go-No Go tasks, deficits in emotional decision making, poor probabilistic reasoning, impaired ability on continuous performance tasks, set shifting, and planning. The clinical phenomenology and neurocognitive deficits are similar to those seen in patients with damage to the orbitofrontal cortex (OFC), which has been reported in functional neuroimaging studies to be abnormal in bipolar mania. Specifically, reduced blood flow to the lateral OFC has been reported, and may reflect dysfunction that leads to the neurocognitive deficits.[47]
In novel environments, both bipolar manic and bipolar euthymic people demonstrate increased activity, exploration and linear movement that is greater than controls, people with ADHD and people with schizophrenia. Using this behavioral pattern in "reverse translational" studies, this behavioral abnormality has been associated with the cholinergic-aminergic hypothesis, which postulates elevated dopaminergic signaling in mania. Reducing the function of DAT using pharmacological or genetic means produces a similar behavioral pattern in animal models. Pharmacological data is consistent with dysfunction of dopamine in bipolar as some studies have reported hypersensitivity to stimulants (however, some studies have found that stimulants effectively attenuate manic behavior, and co-morbid ADHD and bipolar are effectively treated with stimulants),[48] and the mechanism of antimanic drugs may involve attenuating dopamine signalling.[49]
Hypersensitivity of reward systems is consistent across mood states in bipolar, and is evident in the prodrome. Increases in goal directed behavior, risk taking,[50] positive emotions in response to reward, ambitious goal setting and inflexibility in goal directed behaviors are present in euthymia. Neuroimaging studies are consistent with trait hypersensitivity in reward systems, as both mania and depression is associated with elevated resting activity in the striatum, and elevated activity in the striatum and OFC during emotional processing, receipt of reward, and anticipation of reward.[51] Increased activity in the striatum and OFC has also been reported in euthymia during anticipation and receipt of reward, although this finding is extremely inconsistent.[52] These abnormalities may be related to circadian rhythm dysfunction in bipolar, including increased sleep latency, evening preference and poor sleep quality, as the neural systems responsible for both processes are functionally linked.[51] A few lines of evidence suggest that elevated dopamine signaling, possibly due to reduced functionality in DAT, underlie abnormalities in reward function. Dopaminergic drugs such as L-DOPA can precipitate mania, and drugs that attenuate dopaminergic signaling extracellularly (antipsychotics) and intracellularly (lithium) can be efficacious in treating mania. While a large body of translational evidence exists to support DAT hypofunction, in vivo evidence is limited to one study reporting reduced DAT binding in the caudate.[53]
Neuroimaging
Structural
In a review of structural neuroimaging in bipolar disorder, Strakowski proposed dysfunction in an iterative emotional network called the "anterior limbic network", composed of the thalamus, globus pallidus, striatum, ventrolateral prefrontal cortex, ventromedial prefrontal cortex, ACC, amygdala, dorsolateral prefrontal cortex, and cerebellar vermis. Structural imaging studies frequently find abnormalities in these regions which are putatively involved in emotional and cognitive functions that are disrupted in bipolar disorder. For example, while structural neuroimaging studies do not always find abnormal PFC volume in bipolar disorder, when they do, PFC volume is reduced. Furthermore, reduced PFC volume is associated with response inhibition deficits and duration of illness. When the PFC at large is not examined and the focus is narrowed to the orbitofrontal cortex and medial prefrontal cortex, results more consistently observed reductions, although not in bipolar youth. The sgACC volume is observed to be reduced not only in bipolar disorder, but also in unipolar disorder, as well as people with a family history of affective disorders. Enlargement of the striatum and globus pallidus are commonly found, and although some studies fail to observe this, at least one study has reported no volumetric but subtle morphometric abnormalities.[39]
Structural neuroimaging studies consistently report increased frequency of white matter hyperintensities in people with bipolar. However, whether or not the lesions play a causative role is unknown. It is possible that they are a result of secondary factors, such as the processes underlying an increased risk of cardiovascular disease in bipolar. On the other hand, the observation of reduced white matter integrity in frontal-subcortical regions makes it possible that these hyperintensities play a role dysfunction between limbic and cortical regions. Global brain volume and morphology are normal in bipolar. Regional deficits in volume have been reported in ventrolateral and dorsolateral prefrontal regions. Based on this, it has been suggested that reduced limbic regulation by prefrontal regions plays a role in bipolar. Findings related to the volume of the basal ganglia have been inconsistent.
In healthy controls, amygdala volume is inversely related to age. This relationship is reversed in bipolar disorder,[55] and meta analyses have found reduced amygdala volume in pediatric bipolar disorder, and increased amygdala volume in adulthood.[56][57] This is hypothesized to reflect abnormal development of amygdala, possibly involving impaired synaptic pruning, although this may reflect medication or compensatory effects; that is, these abnormalities may not be involved in the mechanism of bipolar, and may instead be a consequence.[58]
A 2016 meta analysis reported that bipolar disorder was associated with grey matter reductions bilaterally in the ACC, vmPFC, and insula extending to the temporal lobe. When compared with grey matter reductions in unipolar depression, significant overlap occurred in the insular and medial prefrontal regions. Although unipolar depression was associated with reductions in the ventral most and dorsal most regions of the mPFC and bipolar with a region near the genu of the corpus callosum, the overlap was still statistically significant.[59] Similar to the overlap with major depression, a significant overlap of bipolar disorder with schizophrenia in grey matter volume reduction occurs in the anterior cingulate cortex, medial prefrontal cortex, lateral prefrontal cortex and bilateral insula.[60]
A 2010 meta analysis of differences in regional grey matter volume between controls and bipolar disorder reported reductions bilaterally in the inferior frontal cortex and insula, which extended more prominently in the right side to include the precentral gyrus, as well as grey matter reductions in the pregenual anterior cingulate cortex (BA24) and anterior cingulate cortex (BA32).[61] One meta analysis reported enlargement of the lateral ventricles and globus pallidus, as well as reductions in hippocampus volume and cross sectional area of the corpus callosum.[62] Another meta analysis reported a similar increase volumes of the globus pallidus and lateral ventricles, as well as increased amygdala volume relative to people with schizophrenia.[63] Reductions have also been reported in the right inferior frontal gyrus, insula, pars triangularis, pars opercularis, and middle and superior temporal gyrus.[64] Structural neuroimaging in people who are susceptible to bipolar disorder (i.e., have a number of relatives with bipolar disorder) have produced few consistent results. Consistent abnormalities in adult first degree relatives include larger insular cortex volumes, while offspring demonstrate increased right inferior frontal gyrus volumes.[65]
The ENIGMA bipolar disorder working group reported cortical thinning in the left Pars opercularis (BA44-inferior frontal gyrus), left fusiform gyrus, left rostral middle frontal cortex, right inferior parietal cortex, along with an increase in the right entorhinal cortex. Duration of illness was associated with reductions bilaterally in the pericalcarine gyrus, left rostral anterior cingulate and right cuneus, along with increases in the right entorhinal cortex. Treatment with lithium was associated with increased cortical thickness bilaterally in the superior parietal gyrus, left paracentral gyrus, and left paracentral lobule. A history of psychosis was associated with reduced surface area in the right frontal pole.[54] Another study on subcortical abnormalities by the same research group reported reductions in the hippocampus, amygdala, and thalamus, along with ventricular enlargement.[66]
One meta analysis reported that when correcting for lithium treatment, which was associated with increased hippocampal volume, people with bipolar demonstrate reduced hippocampus volume.[67]
White matter is reduced in the posterior corpus callosum, regions adjacent to the anterior cingulate, the left optic radiation, and right superior longitudinal tract, and increased in the cerebellum and lentiform nuclei.[68]
Functional
Studies examining resting blood flow, or metabolism generally observed abnormalities dependent upon mood state. Bipolar depression is generally associated with dlPFC and medial orbitofrontal cortex hypometabolism. Less consistent associations include reduced temporal cortex metabolism, increased limbic metabolism and reduced ACC metabolism. Mania is also associated with dlPFC and OFC hypometabolism. Limbic hypermetabolism is more consistent than in bipolar depression, but the overall study quality is low due to limitations associated with neuroimaging in acutely manic patients.[70] Another review reported that mania is generally associated with frontal/ventral hypoactivation, while depression is generally associated with the opposite. A degree of lateralization with regard to abnormalities has been reported, with mania being associated with the right hemisphere, and depression the left. Trait abnormalities in euthymic patients have been observed, including hypoactivity in the ventral prefrontal cortex, and hyperactivity in the amygdala.[71]
During cognitive or emotional tasks, functional neuroimaging studies, consistently find hyperactivation of the basal ganglia, amygdala, and thalamus. Prefrontal abnormalities are less consistently reported, although hyperactivation in the ventral prefrontal cortex is a fairly consistent finding.[72] Hyperactivity in the amygdala and hypoactivity in the medial and ventral prefrontal cortex during exposure to emotional stimuli has been interpreted as reflecting dysfunction in emotional regulation circuits. Increased effective connectivity between the amygdala and orbitofrontal cortex, and elevated striatal responsiveness during reward tasks have been interpreted as hyper-responsiveness in positive emotion and reward circuitry. The abnormal activity in these circuits has been observed in non-emotional tasks, and is congruent with changes in grey and white matter in these circuits.[73] Neural response during reward tasks differentiates unipolar depression from bipolar depression, with the former being associated with reduced neural response and the latter being associated with elevated neural response.[74] An ALE meta analysis of functional neuroimaging comparing adults and adolescents found a larger degree of hyperactivity in the inferior frontal gyrus and precuneus, as well as a larger degree of hypoactivity in the anterior cingulate cortex in adolescents relative to adults[75]
Regardless of mood state, during response inhibition tasks, people with bipolar disorder underactivate the right inferior frontal gyrus. Changes specific on euthymia include hyperactivations in the left superior temporal gyrus and hypoactivations in the basal ganglia, and changes specific to mania include hyperactivation in the basal ganglia.[76] A meta analysis of fMRI studies reported underactivations in the inferior frontal gyrus and putamen and hyperactivation of the parahippocampus, hippocampus, and amygdala. State specific abnormalities were reported for mania and euthymia. During mania, hypoactivation was significant in the inferior frontal gyrus, while euthymia was associated with hypoactivation of the lingual gyrus and hyperactivation of the amygdala.[69]
A meta analysis using region of interest (as opposed to statistical parametric mapping) analysis reported abnormalities across paradigms for euthymic, depressed, and manic subjects. In bipolar mania, reduced activity was reported in the superior, middle, and inferior frontal gyri, while increased activity was reported in the parahippocampal, superior temporal, middle temporal, and inferior temporal gyri. In bipolar depression, reduced activity was reported in the sgACC, ACC, and middle frontal gyrus. In euthymia, reduced activity was reported in the dlPFC, vlPFC, and ACC, while increased activity was reported in the amygdala. During studies examining response to emotional faces, both mania and euthymia were reported to be associated with elevated amygdala activity.[77]
An activation likelihood estimate meta analysis of bipolar studies that used paradigms involving facial emotions reported a number of increases and decreases in activation compared to healthy controls. Elevated activity was reported in the parahippocampal gyrus, putamen, and pulvinar nuclei, while reduced activity was reported bilaterally in the inferior frontal gyrus. Compared to major depressive disorder, bipolar patients overactivated the vACC, pulvinar nucleus, and parahippocampus gyrus/amygdala to a greater degree, while underactivating the dACC. Bipolar subjects overactivated parahippocampus for both fearful and happy expressions, while the caudate and putamen were overactive for happiness and fear respectively. Bipolar subjects also underactivated the ACC for both fearful and happy expressions, while the IFG was underactivated for fearful expressions only. These results were interpreted as reflecting increased engagement with emotionally salient stimuli in bipolar disorder.[78]
Specific symptoms have been linked to various neuroimaging abnormalities in bipolar disorder, as well as schizophrenia. Reality distortion, disorganization, and psychomotor poverty have been linked to prefrontal, thalamic, and striatal regions in both schizophrenia and bipolar (Table 1).[79]
| Symptom dimension | Implicated regions in bipolar | Implicated regions in schizophrenia |
|---|---|---|
| Disorganization |
|
|
| Reality distortion |
|
|
| Psychomotor poverty |
|
|
Frontal cortex
Different regions of the ACC have been studied in the literature, with the subgenual (sgACC) and rostral (rACC) parts being largely separated. Grey matter volume in the sgACC has been, albeit with some exceptions, found to be reduced in bipolar. Along with this, bipolar is associated with increased blood flow in the sgACC that normalizes with treatment. Congruent with these abnormalities is a reduction in glial cells observed in post mortem studies, and reduced integrity of white matter possibly involving a hemispheric imbalance. Findings in the rACC are largely the same as the sgACC (reduced GM, increased metabolism), although more studies have been carried out on protein expression and neuronal morphology. The rACC demonstrates reduced expression NMDA, kainate and GABA related proteins. These findings may be compensating for increased glutaminergic afferents, evidenced by increased Glx in MRS studies. One VBM study reported reduced grey matter in the dACC. Inconsistent results have been found during functional neuroimaging of cognitive tasks, with both decreased and increased activation being observed. Decreased neuron volume and a congruent increase in neural density have been found in the dACC. Reduced expression of markers of neural connectivity have been reported (e.g. synaptophysin, GAP-43), which is congruent with the abnormal structural connectivity observed in the region. [80]
The orbitofrontal cortex demonstrates reduced grey matter, functional activity, GAD67 mRNA, neuronal volume in layer I, and microstructural integrity in people with bipolar.
Although the role of acute mood states is unknown, grey matter volume is generally reported as reduced in the dlPFC, along with resting and task evoked functional signals. Signals of myelination and density of GABAegic neurons is also reduced in the dlPFC, particularly in layers II-V.[81]
Neurochemistry
Magnetic resonance spectroscopy
Increased combined glutamine and glutamate (Glx) have been observed globally, regardless of medication status.[82] Increased Glx has been associated with reduced frontal mismatch negativity, interpreted as dysfunction in NMDA signaling.[83] N-acetyl aspartate levels in the basal ganglia are reduced in bipolar disorder, and trends towards increased in the dorsolateral prefrontal cortex. NAA to creatine ratios are reduced in the hippocampus.[84]
One review of magnetic resonance spectroscopy studies reported increased choline in the basal ganglia, and cingulate as well as a decrease in NAA in the dlPFC and hippocampus. State-specific findings were reported to include elevated phosphomonoesters during acute mood states, and reduced inositol with treatment.[85] Another review reported inositol abnormalities in the basal ganglia, and frontal, temporal and cingulate regions.[86] The finding of a trend towards increased NAA concentrations in the dlPFC may be due to medication status, as treatment with lithium or valproate has been noted to lead to null findings, or even elevated levels of NAA in the frontal cortex. In unmedicated populations, reduced NAA consistently found in the prefrontal cortex, particularly the dlPFC.[87]
One meta-analysis reported no changes in MRS measured GABA in bipolar disorder.[88]
Monoamines
Various hypotheses related to monoamines have been proposed. The biogenic amine hypothesis posits general dysregulation of monoamines underlies bipolar and affective disorders. The cholinergic aminergic balance hypothesis posits that an increased ratio of cholinergic activity relative to adrenergic signaling underlies depression, while increased adrenergic signaling relative to cholinergic signaling underlies mania. The permissive hypothesis suggests that serotonin is necessary but not sufficient for affective symptoms, and that reduced serotonergic tone is common to both depression and mania.[89]
Studies of the binding potential of dopamine receptor D2 and dopamine transporter have been inconsistent but dopamine receptor D1's binding potential has been observed to be decreased. Drugs that release dopamine produce effects similar to mania, leading some to hypothesize that mania involves increased catecholaminergic signalling. Dopamine has also been implicated through genetic "reverse translational" studies demonstrating an association between reduced DAT functionality and manic symptoms. The binding potential of muscarinic receptors are reduced in vivo during depression, as well as in post mortem studies, supporting the cholinergic aminergic balance hypothesis.[90]
The role of monoamines in bipolar have been studied using neurotransmitter metabolites. Reduced concentration of homovanillic acid, the primary metabolite of dopamine, in the cerebrospinal fluid (CSF) of people with depression is consistently reported. This finding is related to psychomotor retardation and anhedonia. Furthermore, parkinson's disease is associated with high rates of depression, and one case study has reported the abolishment of parkinson's symptoms during manic episodes. The binding potential of VMAT2 is also elevated in bipolar I patients with a history of psychosis, although this finding is inconsistent with finding that valproate increases VMAT2 expression in rodents.[91] One study on DAT binding in acutely depressed people with bipolar reported reductions in the caudate but not putamen.[92]
Studies of serotonin's primary metabolite 5-HIAA have been inconsistent,[93] although limited evidence points towards reduced central serotonin signaling in a subgroup of aggressive or suicidal patients.[91] Studies assessing the binding potential of the serotonin transporter or serotonin receptors have also been inconsistent, but generally point towards abnormal serotonin signaling.[94] One study reported both increased SERT binding in the insula, mPFC, ACC and thalamus, and decreased SERT binding in the raphe nuclei in acutely depressed bipolar.[92] Serotonin may play a role in mania by increasing the salience of stimuli related to reward.[95]
One more line of evidence that suggests a role of monoamines in bipolar is the process of antidepressant related affective switches. Selective serotonin reuptake inhibitors and more frequently, tricyclic antidepressants are associated with between a 10%-70% risk of affective switch from depression to mania or hypomania, depending upon the criteria used. The more robust association between TCAs and affective switches, as opposed to more selective drugs, has been interpreted as indicating that more extensive perturbation in monoamine systems is associated with more frequent mood switching.[96]
Hypothalamic pituitary adrenal axis
Bipolar disorder is associated with elevated basal and dexamethasone elicited cortisol and adrenocorticotropic hormone (ACTH). These abnormalities are particularly prominent in mania, and are inversely associated with antipsychotic use.[97] The incidence of psychiatric symptoms associated with corticosteroids is between 6% and 32%. Corticosteroids may precipitate mania, supporting the role of the HPA axis in affective episodes.[96] Measures from urinary versus salivary cortisol have been contradictory, with one study of the former concluding that HPA hyperactivity was a trait marker, while a study of the latter concluded that no difference in HPA activity exists in remission.[98] Measurement during the morning are thought to be more sensitive due to the cortisol awakening response. Studies are generally more consistent, and observe HPA hyperactivity.[98]
Neurotrophic factors
Brain derived neurotrophic factor levels are peripherally reduced in both manic and depressive phases.[99]
Opioid system
Manic bipolar (type one) patients show higher mu opioid receptor gene expression than "healthy controls".[100]
Intracellular signaling
The levels of Gαs but not other G proteins is increased in the frontal, temporal and occipital cortices. The binding of serotonin receptors to G proteins is also elevated globally. Leukocyte and platelet levels of Gαs and Gαi are also elevated in those with bipolar disorder. Downstream targets of G protein signaling are also altered in bipolar disorder. Increased levels of adenylyl cyclase, protein kinase A (PKA), and cyclic adenosine monophosphate induced PKA activity are also reported. Phosphoinositide signaling is also altered, with elevated levels of phospholipase C, protein kinase C, and Gαq being reported in bipolar.[101] Elevated cAMP stimulated phosphorylation or Rap1 (a substrate of PKA), along with increased levels of Rap1 have been reported in peripherally collected cells of people with bipolar. Increased coupling of serotonin receptors to G proteins has been observed. While linkage studies performed on genes related to G protein signaling, as well as studies on post mortem mRNA concentration fail to report an association with bipolar disorder, the overall evidence suggests abnormal coupling of neurotransmission systems with G proteins.[102]
Mania may be specifically associated with protein kinase C hyperactivity, although most evidence for this mechanism is indirect. The gene DGKH has been reported in genome wide association studies to be related to bipolar disorder, and it is known to be involved in PKC regulation. Manipulation of PKC in animals produces behavioral phenotypes similar to mania, and PKC inhibition is a plausible mechanism of action for mood stabilizers. Overactive PKC signalling may lead to long term structural changes in the frontal cortex as well, potentially leading to progression of manic symptoms.[103][104]
Glycogen synthase kinase 3 has been implicated in bipolar disorder, as bipolar medications lithium and valproate have been shown to increase its phosphorylation, thereby inhibiting it. However, some postmortem studies have not shown any differences in GSK-3 levels or the levels of a downstream target β-catenin.[101] In contrast, one review reported a number of studies observing reduced expression of β-catenin and GSK3 mRNA in the prefrontal and temporal cortex.[105]
Excessive response of arachidonic acid signaling cascades in response to stimulation by dopamine receptor D2 or NMDA receptors may be involved in bipolar mania. The evidence for this is primarily pharmacological, based on the observation that drugs that are effective in treating bipolar reduced AA cascade magnitude, while drugs that exacerbate bipolar do the opposite.[106]
Calcium homeostasis may be impaired across all mood states. Elevated basal intracellular, and provoked calcium concentrations in platelets and transformed lymphoblasts are found in people with bipolar. Serum concentrations of calcium are also elevated, and abnormal calcium concentrations in response to stimulation of olfactory neurons is also observed. These findings are congruent with the genetic association of bipolar with CACNAC1, an L-type calcium channel,[102] as well as the efficacy of anti-epileptic agents.[107] Normal platelets placed in plasma from people with bipolar disorder do not demonstrate elevated levels of intracellular calcium, indicating that dysfunction lies intracellularly. One possible mechanism is that elevated inositol triphosphate (IP3) caused by hyperactive neuronal calcium sensor 1 causes excessive calcium release.[31] Serum levels of S100B (a calcium binding protein) are elevated in bipolar mania.[108]
Mitochondrial dysfunction
Some researchers have suggested bipolar disorder is a mitochondrial disease. Some cases of familial chronic progressive external ophthalmoplegia demonstrate increased rates of bipolar disorder before the onset of CPEO, and the higher rate of maternal inheritance patterns support this hypothesis.[109] Downregulation of genes encoding for mitochondrial subunits, decreased concentration of phosphocreatine, decreased brain pH, and elevated lactate concentrations have also been reported. Mitochondrial dysfunction may be related to elevated levels of the lipid peroxidation marker thiobarbituric acid reactive substances, which are attenuated by lithium treatment.[110]
Neuropathology
A number of abnormalities in GABAergic neurons have been reported in people with bipolar disorder. People with bipolar demonstrate reduced expression of GAD67 in CA3/CA2 subregion of the hippocampus. More extensive reductions of other indicators of GABA function have been reported in the CA4 and CA1. Abnormal expression of kainate receptors on GABAergic cells have been reported, with reductions in GRIK1 and GRIK2 mRNA in the CA2/CA3 being found in people with bipolar. Decreased levels of HCN channels have also been reported, which, along with abnormal glutamate signaling, could contribute to reduced GABAergic tone in the hippocampus.[111]
The observation of increased Glx in the prefrontal cortex is congruent with the observation of reduced glial cell counts and prefrontal cortex volume, as glia play an important role in glutamate homeostasis.[112] Although the number and quality of studies examining NMDA receptor subunits is poor, evidence for reduced NMDA signaling and reduced contribution from the NR2A subunit is consistent.[113]
Decreased neuron density and soma size in the ACC and dlPFC has been observed. The dlPFC also demonstrates reduced glial density, a finding that is less consistent in the ACC. The reduction in cell volume may be due to early stage apoptosis, a mechanism that is supported by studies observing reduced anti-apoptotic gene expression in both peripheral cells and neurons, as well as the reduction in BDNF that is consistently found in bipolar.[114] Reductions in cortical glia are not found across the whole cortex (e.g. somatosensory areas demonstrate normal glial density and counts), indicating that systematic dysfunction in glial cells is not likely; rather, abnormal functionality of connectivity in specific regions may result in abnormal glia, which may in turn exacerbate dysfunction.[115]
Dendritic atrophy and loss of oligodendrocytes is found in the medial prefrontal cortex, and is possibly specific to GABAergic neurons.[116]
Immune dysfunction
Elevated levels of IL-6, C-reactive protein (CRP) and TNFα have been reported in bipolar. Levels of some (IL-6 and CRP) but not all (TNFα) may be reduced by treatment. Increases in IL-6 have been reported in mood episodes, regardless of polarity.[117] Inflammation has been consistently reported in bipolar disorder, and the progressive nature lies in dysregulation of NF-κB.[118]
See also
References
- ↑ Maletic, V; Raison, C (2014). "Integrated neurobiology of bipolar disorder". Frontiers in Psychiatry. 5: 98. doi:10.3389/fpsyt.2014.00098. PMC 4142322. PMID 25202283.
- ↑ Townsend, J; Altshuler, LL (June 2012). "Emotion processing and regulation in bipolar disorder: a review". Bipolar Disorders. 14 (4): 326–39. doi:10.1111/j.1399-5618.2012.01021.x. PMID 22631618. S2CID 21769040.
- ↑ Newberg, AR; Catapano, LA; Zarate, CA; Manji, HK (January 2008). "Neurobiology of bipolar disorder". Expert Review of Neurotherapeutics. 8 (1): 93–110. doi:10.1586/14737175.8.1.93. PMID 18088203. S2CID 12620338.
- ↑ Cousins, DA; Grunze, H (March 2012). "Interpreting magnetic resonance imaging findings in bipolar disorder". CNS Neuroscience & Therapeutics. 18 (3): 201–7. doi:10.1111/j.1755-5949.2011.00280.x. PMC 6493435. PMID 22449107.
- ↑ Buxbaum, Joseph; Charney, Dennis; Sklar, Pamela; Nestler, Eric. Charney & Nestler's Neurobiology of Mental Illness. Oxford University Press. p. 162.
- 1 2 Sklar, P. "The Genetics of Schizophrenia and Bipolar Disorder". In Charney, D; Buxmaum, J; Nestler, E (eds.). Neurobiology of Mental Illness. Oxford University Press.
- ↑ Bearden, C; Zandi, P; Freimer, N. "Molecular Architecture and Neurobiology of Bipolar Disorder". In Lehner, T; Miller, B; State, M (eds.). Genomics, Circuits, and Pathways in Neuropsychiatry. Elsevier.
- ↑ Ferreira, MA; O'Donovan, MC; Meng, YA; Jones, IR; Ruderfer, DM; Jones, L; Fan, J; Kirov, G; Perlis, RH; Green, EK; Smoller, JW; Grozeva, D; Stone, J; Nikolov, I; Chambert, K; Hamshere, ML; Nimgaonkar, VL; Moskvina, V; Thase, ME; Caesar, S; Sachs, GS; Franklin, J; Gordon-Smith, K; Ardlie, KG; Gabriel, SB; Fraser, C; Blumenstiel, B; Defelice, M; Breen, G; Gill, M; Morris, DW; Elkin, A; Muir, WJ; McGhee, KA; Williamson, R; MacIntyre, DJ; MacLean, AW; St, CD; Robinson, M; Van Beck, M; Pereira, AC; Kandaswamy, R; McQuillin, A; Collier, DA; Bass, NJ; Young, AH; Lawrence, J; Ferrier, IN; Anjorin, A; Farmer, A; Curtis, D; Scolnick, EM; McGuffin, P; Daly, MJ; Corvin, AP; Holmans, PA; Blackwood, DH; Gurling, HM; Owen, MJ; Purcell, SM; Sklar, P; Craddock, N; Wellcome Trust Case Control, Consortium. (September 2008). "Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder". Nature Genetics. 40 (9): 1056–8. doi:10.1038/ng.209. PMC 2703780. PMID 18711365.
- ↑ Charney, AW; Ruderfer, DM; Stahl, EA; Moran, JL; Chambert, K; Belliveau, RA; Forty, L; Gordon-Smith, K; Di Florio, A; Lee, PH; Bromet, EJ; Buckley, PF; Escamilla, MA; Fanous, AH; Fochtmann, LJ; Lehrer, DS; Malaspina, D; Marder, SR; Morley, CP; Nicolini, H; Perkins, DO; Rakofsky, JJ; Rapaport, MH; Medeiros, H; Sobell, JL; Green, EK; Backlund, L; Bergen, SE; Juréus, A; Schalling, M; Lichtenstein, P; Roussos, P; Knowles, JA; Jones, I; Jones, LA; Hultman, CM; Perlis, RH; Purcell, SM; McCarroll, SA; Pato, CN; Pato, MT; Craddock, N; Landén, M; Smoller, JW; Sklar, P (10 January 2017). "Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder". Translational Psychiatry. 7 (1): e993. doi:10.1038/tp.2016.242. PMC 5545718. PMID 28072414.
- ↑ Psychiatric GWAS Consortium Bipolar Disorder Working, Group. (18 September 2011). "Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4". Nature Genetics. 43 (10): 977–83. doi:10.1038/ng.943. PMC 3637176. PMID 21926972.
- ↑ Mühleisen, TW; Leber, M; Schulze, TG; Strohmaier, J; Degenhardt, F; Treutlein, J; Mattheisen, M; Forstner, AJ; Schumacher, J; Breuer, R; Meier, S; Herms, S; Hoffmann, P; Lacour, A; Witt, SH; Reif, A; Müller-Myhsok, B; Lucae, S; Maier, W; Schwarz, M; Vedder, H; Kammerer-Ciernioch, J; Pfennig, A; Bauer, M; Hautzinger, M; Moebus, S; Priebe, L; Czerski, PM; Hauser, J; Lissowska, J; Szeszenia-Dabrowska, N; Brennan, P; McKay, JD; Wright, A; Mitchell, PB; Fullerton, JM; Schofield, PR; Montgomery, GW; Medland, SE; Gordon, SD; Martin, NG; Krasnow, V; Chuchalin, A; Babadjanova, G; Pantelejeva, G; Abramova, LI; Tiganov, AS; Polonikov, A; Khusnutdinova, E; Alda, M; Grof, P; Rouleau, GA; Turecki, G; Laprise, C; Rivas, F; Mayoral, F; Kogevinas, M; Grigoroiu-Serbanescu, M; Propping, P; Becker, T; Rietschel, M; Nöthen, MM; Cichon, S (11 March 2014). "Genome-wide association study reveals two new risk loci for bipolar disorder". Nature Communications. 5: 3339. Bibcode:2014NatCo...5.3339M. doi:10.1038/ncomms4339. hdl:1959.4/unsworks_13067. PMID 24618891.
- ↑ Chen, DT; Jiang, X; Akula, N; Shugart, YY; Wendland, JR; Steele, CJ; Kassem, L; Park, JH; Chatterjee, N; Jamain, S; Cheng, A; Leboyer, M; Muglia, P; Schulze, TG; Cichon, S; Nöthen, MM; Rietschel, M; BiGS.; McMahon, FJ; Farmer, A; McGuffin, P; Craig, I; Lewis, C; Hosang, G; Cohen-Woods, S; Vincent, JB; Kennedy, JL; Strauss, J (February 2013). "Genome-wide association study meta-analysis of European and Asian-ancestry samples identifies three novel loci associated with bipolar disorder". Molecular Psychiatry. 18 (2): 195–205. doi:10.1038/mp.2011.157. PMID 22182935.
- ↑ Craddock, N; Sklar, P (11 May 2013). "Genetics of bipolar disorder". Lancet. 381 (9878): 1654–62. doi:10.1016/S0140-6736(13)60855-7. PMID 23663951. S2CID 9502929.
- ↑ Kishi, T; Yoshimura, R; Fukuo, Y; Kitajima, T; Okochi, T; Matsunaga, S; Inada, T; Kunugi, H; Kato, T; Yoshikawa, T; Ujike, H; Umene-Nakano, W; Nakamura, J; Ozaki, N; Serretti, A; Correll, CU; Iwata, N (November 2011). "The CLOCK gene and mood disorders: a case-control study and meta-analysis". Chronobiology International. 28 (9): 825–33. doi:10.3109/07420528.2011.609951. PMID 22080789. S2CID 84432102.
- ↑ McCarthy, MJ; Nievergelt, CM; Kelsoe, JR; Welsh, DK (2012). "A survey of genomic studies supports association of circadian clock genes with bipolar disorder spectrum illnesses and lithium response". PLOS ONE. 7 (2) e32091. Bibcode:2012PLoSO...732091M. doi:10.1371/journal.pone.0032091. PMC 3285204. PMID 22384149.
- ↑ Jiang, HY; Qiao, F; Xu, XF; Yang, Y; Bai, Y; Jiang, LL (9 August 2013). "Meta-analysis confirms a functional polymorphism (5-HTTLPR) in the serotonin transporter gene conferring risk of bipolar disorder in European populations". Neuroscience Letters. 549: 191–6. doi:10.1016/j.neulet.2013.05.065. PMID 23756178. S2CID 45915304.
- ↑ Gao, J; Jia, M; Qiao, D; Qiu, H; Sokolove, J; Zhang, J; Pan, Z (March 2016). "TPH2 gene polymorphisms and bipolar disorder: A meta-analysis". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 171B (2): 145–52. doi:10.1002/ajmg.b.32381. PMID 26365518. S2CID 9467242.
- ↑ Grunze, H. "Bipolar Disorder". In Zigmond, M; Rowland, L; Coyle, J (eds.). Neurobiology of Brain Disorder: Biological Basis of Neurological and Psychiatric Disorders. Elsevier.
- ↑ Harrison, PJ (February 2016). "Molecular neurobiological clues to the pathogenesis of bipolar disorder". Current Opinion in Neurobiology. 36: 1–6. doi:10.1016/j.conb.2015.07.002. PMC 4779149. PMID 26210959.
- ↑ Wang, Z; Li, Z; Gao, K; Fang, Y (24 December 2014). "Association between brain-derived neurotrophic factor genetic polymorphism Val66Met and susceptibility to bipolar disorder: a meta-analysis". BMC Psychiatry. 14: 366. doi:10.1186/s12888-014-0366-9. PMC 4297385. PMID 25539739.
- ↑ González-Castro, TB; Nicolini, H; Lanzagorta, N; López-Narváez, L; Genis, A; Pool García, S; Tovilla-Zárate, CA (February 2015). "The role of brain-derived neurotrophic factor (BDNF) Val66Met genetic polymorphism in bipolar disorder: a case-control study, comorbidities, and meta-analysis of 16,786 subjects". Bipolar Disorders. 17 (1): 27–38. doi:10.1111/bdi.12227. PMID 25041243.
- ↑ Torkamani, A; Topol, EJ; Schork, NJ (November 2008). "Pathway analysis of seven common diseases assessed by genome-wide association". Genomics. 92 (5): 265–72. doi:10.1016/j.ygeno.2008.07.011. PMC 2602835. PMID 18722519.
- ↑ Pedroso, I; Lourdusamy, A; Rietschel, M; Nöthen, MM; Cichon, S; McGuffin, P; Al-Chalabi, A; Barnes, MR; Breen, G (15 August 2012). "Common genetic variants and gene-expression changes associated with bipolar disorder are over-represented in brain signaling pathway genes". Biological Psychiatry. 72 (4): 311–7. doi:10.1016/j.biopsych.2011.12.031. PMID 22502986. S2CID 30065607.
- ↑ Nurnberger JI, Jr; Koller, DL; Jung, J; Edenberg, HJ; Foroud, T; Guella, I; Vawter, MP; Kelsoe, JR; Psychiatric Genomics Consortium Bipolar, Group. (June 2014). "Identification of pathways for bipolar disorder: a meta-analysis". JAMA Psychiatry. 71 (6): 657–64. doi:10.1001/jamapsychiatry.2014.176. PMC 4523227. PMID 24718920.
- ↑ Frans EM, Sandin S, Reichenberg A, Lichtenstein P, Långström N, Hultman CM (2008). "Advancing Paternal Age and Bipolar Disorder". Archives of General Psychiatry. 65 (9): 1034–1040. doi:10.1001/archpsyc.65.9.1034. PMID 18762589.
- 1 2 Goh, XX; Tang, PY; Tee, SF (Jul 2021). "8-Hydroxy-2'-Deoxyguanosine and Reactive Oxygen Species as Biomarkers of Oxidative Stress in Mental Illnesses: A Meta-Analysis". Psychiatry Investig. 18 (7): 603–618. doi:10.30773/pi.2020.0417. PMC 8328836. PMID 34340273.
- 1 2 Young, JW; Dulcis, D (15 July 2015). "Investigating the mechanism(s) underlying switching between states in bipolar disorder". European Journal of Pharmacology. 759: 151–62. doi:10.1016/j.ejphar.2015.03.019. PMC 4437855. PMID 25814263.
- ↑ Smith, Daniel; Whitham, Elizabeth; Ghaemi, Nassir (2012). "Bipolar Disorder". In Schlaepfer, Thomas; Nemeroff, Charles (eds.). Neurobiology of Psychiatric Disorders (1st ed.). Elsevier. ISBN 978-0-444-53500-9.
- ↑ Bostock, EC; Kirkby, KC; Garry, MI; Taylor, BV (1 September 2015). "Comparison of precipitating factors for mania and partial seizures: Indicative of shared pathophysiology?". Journal of Affective Disorders. 183: 57–67. doi:10.1016/j.jad.2015.04.057. PMID 26001664.
- 1 2 Satzer, D; Bond, DJ (May 2016). "Mania secondary to focal brain lesions: implications for understanding the functional neuroanatomy of bipolar disorder". Bipolar Disorders. 18 (3): 205–20. doi:10.1111/bdi.12387. PMID 27112231. S2CID 21210920.
- 1 2 Dubovsky, SL (June 2015). "Mania". Continuum (Minneapolis, Minn.). 21 (3 Behavioral Neurology and Neuropsychiatry): 737–55. doi:10.1212/01.CON.0000466663.28026.6f. PMID 26039851. S2CID 220583962.
- ↑ Savitz, J; Drevets, W (2011). "Neuroimaging and Neuropathological Findings in Bipolar Disorder". In H, Manji; Zarate, C (eds.). Behavioral Neurobiology of Bipolar Disorder and its Treatment. Springer. p. 200.
- ↑ Strakowski, Stephen M (2014). "Neurophysiology of Bipolar Disorder". Bipolar Disorder. New York: Oxford University Press. p. 36. ISBN 978-0-19-999568-4.
- ↑ Strakowski, SM; Adler, CM; Almeida, J; Altshuler, LL; Blumberg, HP; Chang, KD; DelBello, MP; Frangou, S; McIntosh, A; Phillips, ML; Sussman, JE; Townsend, JD (June 2012). "The functional neuroanatomy of bipolar disorder: a consensus model". Bipolar Disorders. 14 (4): 313–25. doi:10.1111/j.1399-5618.2012.01022.x. PMC 3874804. PMID 22631617.
- ↑ Cerullo, MA; Adler, CM; Delbello, MP; Strakowski, SM (2009). "The functional neuroanatomy of bipolar disorder". International Review of Psychiatry. 21 (4): 314–22. doi:10.1080/09540260902962107. PMID 20374146. S2CID 42049948.
- ↑ DelBello, MP; Adler, CM; Strakowski, SM (April 2006). "The neurophysiology of childhood and adolescent bipolar disorder". CNS Spectrums. 11 (4): 298–311. doi:10.1017/s1092852900020794. PMID 16641835. S2CID 10161379.
- ↑ Strakowski, SM; Delbello, MP; Adler, CM (January 2005). "The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings". Molecular Psychiatry. 10 (1): 105–16. doi:10.1038/sj.mp.4001585. PMID 15340357.
- ↑ Adler, CM; DelBello, MP; Strakowski, SM (April 2006). "Brain network dysfunction in bipolar disorder". CNS Spectrums. 11 (4): 312–20, quiz 323–4. doi:10.1017/s1092852900020800. PMID 16641836. S2CID 39515416.
- 1 2 Strakowski, Stephen M. (2011). "Structural Imaging of Bipolar Illness". In Shenton, Martha E; Turetsky, Bruce I (eds.). Understanding Neuropsychiatric Disorders: Insights From Neuroimaging. New York: Cambridge University Press. ISBN 978-0-521-89942-0.
- ↑ Green, MJ; Cahill, CM; Malhi, GS (November 2007). "The cognitive and neurophysiological basis of emotion dysregulation in bipolar disorder". Journal of Affective Disorders. 103 (1–3): 29–42. doi:10.1016/j.jad.2007.01.024. PMID 17328959.
- 1 2 Blond, BN; Fredericks, CA; Blumberg, HP (June 2012). "Functional neuroanatomy of bipolar disorder: structure, function, and connectivity in an amygdala-anterior paralimbic neural system". Bipolar Disorders. 14 (4): 340–55. doi:10.1111/j.1399-5618.2012.01015.x. PMC 3880745. PMID 22631619.
- ↑ Wiglusz, MS; Landowski, J; Cubała, WJ; Agius, M (September 2015). "Overlapping phenomena of bipolar disorder and epilepsy--a common pharmacological pathway". Psychiatria Danubina. 27 (Suppl 1): S177–81. PMID 26417756.
- ↑ Mazza, M; Di Nicola, M; Della Marca, G; Janiri, L; Bria, P; Mazza, S (August 2007). "Bipolar disorder and epilepsy: a bidirectional relation? Neurobiological underpinnings, current hypotheses, and future research directions". The Neuroscientist. 13 (4): 392–404. doi:10.1177/10738584070130041101. PMID 17644769. S2CID 1464414.
- ↑ Brooks, John O; Wang, PoW; Ketter, Terence A (2010). "Functional Brain Imaging Studies in Bipolar Disorder: Focus on Cerebral Metabolism and Blood Flow". In Yatham, Lakshmi N; Maj, Mario (eds.). Bipolar Disorder: Clinical and Neurobiology Foundations. Wiley Blackwell. ISBN 978-0-470-72198-8.
- ↑ Fredericks, Carolyn A; Kalmar, Jessica H; Blumberg, Hilary P (2006). "The role of the ventral prefrontal cortex in mood disorders". In Zald, David H; Rauch, Scott L (eds.). The Orbitofrontal Cortex. New York: Oxford University Press. pp. 552–553. ISBN 978-0-19-856574-1.
- ↑ Murphy, F. C.; Sahakian, B. J. (2001). "Neuropsychology of bipolar disorder". British Journal of Psychiatry. 178 (S41): s120–s127. doi:10.1192/bjp.178.41.s120. PMID 11388950.
- ↑ Clark, L; Sahakian, BJ (2008). "Cognitive neuroscience and brain imaging in bipolar disorder". Dialogues in Clinical Neuroscience. 10 (2): 153–63. doi:10.31887/DCNS.2008.10.2/lclark. PMC 3181872. PMID 18689286.
- ↑ Hegerl, Ulrich; Sander, Christian; Hensch, Tilman. "Arousal Regulation in Affective Disorders". In Frodl, Thomas (ed.). Systems Neuroscience in Depression. Elsevier Science. p. 353.
In conclusion, stimulants in bipolar disorder seem to be relatively safe, and there are even several case reports suggesting rapid antimanic effects of psychostimulants (Beckmann & Heinemann, 1976; Garvey, Hwang, Teubner-Rhodes, Zander, & Rhem, 1987; Max, Richards, & Hamdanallen, 1995). In a study by Bschor, Müller-Oerlinghausen, and Ulrich (2001), improvement of manic symptoms occurred about 2 h after oral intake of methylphenidate in a manic patient with signs of unstable EEG-vigilance regulation. Three months later, when the patient was admitted anew, a rapid antimanic effect was again shown after re-exposition to methylphenidate
- ↑ van Enkhuizen, J; Geyer, MA; Minassian, A; Perry, W; Henry, BL; Young, JW (November 2015). "Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies". Neuroscience and Biobehavioral Reviews. 58: 4–18. doi:10.1016/j.neubiorev.2015.08.008. PMC 4684462. PMID 26297513.
- ↑ Edge, MD; Johnson, SL; Ng, T; Carver, CS (15 August 2013). "Iowa Gambling Task performance in euthymic bipolar I disorder: a meta-analysis and empirical study". Journal of Affective Disorders. 150 (1): 115–22. doi:10.1016/j.jad.2012.11.027. PMC 3716836. PMID 23219060.
- 1 2 Alloy, LB; Nusslock, R; Boland, EM (2015). "The development and course of bipolar spectrum disorders: an integrated reward and circadian rhythm dysregulation model". Annual Review of Clinical Psychology. 11: 213–50. doi:10.1146/annurev-clinpsy-032814-112902. PMC 4380533. PMID 25581235.
- ↑ Rizvi, SJ; Lambert, C; Kennedy, S (8 March 2018). "Presentation and Neurobiology of Anhedonia in Mood Disorders: Commonalities and Distinctions". Current Psychiatry Reports. 20 (2): 13. doi:10.1007/s11920-018-0877-z. PMID 29520717. S2CID 3886617.
- ↑ Whitton, AE; Treadway, MT; Pizzagalli, DA (January 2015). "Reward processing dysfunction in major depression, bipolar disorder and schizophrenia". Current Opinion in Psychiatry. 28 (1): 7–12. doi:10.1097/YCO.0000000000000122. PMC 4277233. PMID 25415499.
- 1 2 Hibar, D P; Westlye, L T; Doan, N T; Jahanshad, N; Cheung, J W; Ching, C R K; Versace, A; Bilderbeck, A C; Uhlmann, A; Mwangi, B; Krämer, B; Overs, B; Hartberg, C B; Abé, C; Dima, D; Grotegerd, D; Sprooten, E; Bøen, E; Jimenez, E; Howells, F M; Delvecchio, G; Temmingh, H; Starke, J; Almeida, J R C; Goikolea, J M; Houenou, J; Beard, L M; Rauer, L; Abramovic, L; et al. (2 May 2017). "Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group". Molecular Psychiatry. 23 (4): 932–942. doi:10.1038/mp.2017.73. PMC 5668195. PMID 28461699.
- ↑ Usher, J; Leucht, S; Falkai, P; Scherk, H (30 April 2010). "Correlation between amygdala volume and age in bipolar disorder - a systematic review and meta-analysis of structural MRI studies". Psychiatry Research. 182 (1): 1–8. doi:10.1016/j.pscychresns.2009.09.004. PMID 20226638. S2CID 25194888.
- ↑ Pfeifer, JC; Welge, J; Strakowski, SM; Adler, CM; DelBello, MP (November 2008). "Meta-analysis of amygdala volumes in children and adolescents with bipolar disorder". Journal of the American Academy of Child and Adolescent Psychiatry. 47 (11): 1289–98. doi:10.1097/CHI.0b013e318185d299. PMID 18827720.
- ↑ Strakowski, Stephen M (2014). "Neurophysiology of Bipolar Disorder". Bipolar Disorder. New York: Oxford University Press. p. 35. ISBN 978-0-19-999568-4.
- ↑ Brambilla, Paolo; Soares, Jair (2010-10-11). "Structural Brain Imaging in Bipolar Disorder". In Lakshmi, Yatham; Maj, Mario (eds.). Bipolar Disorder: Clinical and Neurobiology Foundations. Wiley Blackwell. ISBN 978-0-470-72198-8.
- ↑ Wise, T; Radua, J; Via, E; Cardoner, N; Abe, O; Adams, TM; Amico, F; Cheng, Y; Cole, JH; de Azevedo Marques Périco, C; Dickstein, DP; Farrow, TFD; Frodl, T; Wagner, G; Gotlib, IH; Gruber, O; Ham, BJ; Job, DE; Kempton, MJ; Kim, MJ; Koolschijn, PCMP; Malhi, GS; Mataix-Cols, D; McIntosh, AM; Nugent, AC; O'Brien, JT; Pezzoli, S; Phillips, ML; Sachdev, PS; Salvadore, G; Selvaraj, S; Stanfield, AC; Thomas, AJ; van Tol, MJ; van der Wee, NJA; Veltman, DJ; Young, AH; Fu, CH; Cleare, AJ; Arnone, D (October 2017). "Common and distinct patterns of grey-matter volume alteration in major depression and bipolar disorder: evidence from voxel-based meta-analysis". Molecular Psychiatry. 22 (10): 1455–1463. doi:10.1038/mp.2016.72. PMC 5622121. PMID 27217146.
- ↑ Heckers, Stephan; Woodward, Neil; Öngür, Dost (2018). "Neuroimaging of Psychotic Disorders". In Sklar, Pamela; Charney, Dennis; Buxbaum, Joseph; Nestler, Eric (eds.). Neurobiology of Mental Illness (5th ed.). Oxford University Press. ISBN 978-0-19-068142-5.
- ↑ Bora, E; Fornito, A; Yücel, M; Pantelis, C (1 June 2010). "Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder". Biological Psychiatry. 67 (11): 1097–105. doi:10.1016/j.biopsych.2010.01.020. PMID 20303066. S2CID 24812539.
- ↑ Kempton, MJ; Geddes, JR; Ettinger, U; Williams, SC; Grasby, PM (September 2008). "Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder". Archives of General Psychiatry. 65 (9): 1017–32. doi:10.1001/archpsyc.65.9.1017. PMID 18762588.
- ↑ Arnone, D; Cavanagh, J; Gerber, D; Lawrie, SM; Ebmeier, KP; McIntosh, AM (September 2009). "Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis". The British Journal of Psychiatry. 195 (3): 194–201. doi:10.1192/bjp.bp.108.059717. PMID 19721106.
- ↑ Selvaraj, S; Arnone, D; Job, D; Stanfield, A; Farrow, TF; Nugent, AC; Scherk, H; Gruber, O; Chen, X; Sachdev, PS; Dickstein, DP; Malhi, GS; Ha, TH; Ha, K; Phillips, ML; McIntosh, AM (March 2012). "Grey matter differences in bipolar disorder: a meta-analysis of voxel-based morphometry studies". Bipolar Disorders. 14 (2): 135–45. doi:10.1111/j.1399-5618.2012.01000.x. PMID 22420589. S2CID 2548825.
- ↑ Nery, FG; Monkul, ES; Lafer, B (December 2013). "Gray matter abnormalities as brain structural vulnerability factors for bipolar disorder: A review of neuroimaging studies of individuals at high genetic risk for bipolar disorder". The Australian and New Zealand Journal of Psychiatry. 47 (12): 1124–35. doi:10.1177/0004867413496482. PMID 23864160. S2CID 235255.
- ↑ Hibar, DP; Westlye, LT; van Erp, TG; Rasmussen, J; Leonardo, CD; Faskowitz, J; Haukvik, UK; Hartberg, CB; Doan, NT; Agartz, I; Dale, AM; Gruber, O; Krämer, B; Trost, S; Liberg, B; Abé, C; Ekman, CJ; Ingvar, M; Landén, M; Fears, SC; Freimer, NB; Bearden, CE; Costa Rica/Colombia Consortium for Genetic Investigation of Bipolar, Endophenotypes.; Sprooten, E; Glahn, DC; Pearlson, GD; Emsell, L; Kenney, J; Scanlon, C; McDonald, C; Cannon, DM; Almeida, J; Versace, A; Caseras, X; Lawrence, NS; Phillips, ML; Dima, D; Delvecchio, G; Frangou, S; Satterthwaite, TD; Wolf, D; Houenou, J; Henry, C; Malt, UF; Bøen, E; Elvsåshagen, T; Young, AH; Lloyd, AJ; Goodwin, GM; Mackay, CE; Bourne, C; Bilderbeck, A; Abramovic, L; Boks, MP; van Haren, NE; Ophoff, RA; Kahn, RS; Bauer, M; Pfennig, A; Alda, M; Hajek, T; Mwangi, B; Soares, JC; Nickson, T; Dimitrova, R; Sussmann, JE; Hagenaars, S; Whalley, HC; McIntosh, AM; Thompson, PM; Andreassen, OA (December 2016). "Subcortical volumetric abnormalities in bipolar disorder". Molecular Psychiatry. 21 (12): 1710–1716. doi:10.1038/mp.2015.227. PMC 5116479. PMID 26857596.
- ↑ Hajek, T; Kopecek, M; Höschl, C; Alda, M (September 2012). "Smaller hippocampal volumes in patients with bipolar disorder are masked by exposure to lithium: a meta-analysis". Journal of Psychiatry & Neuroscience. 37 (5): 333–43. doi:10.1503/jpn.110143. PMC 3447132. PMID 22498078.
- ↑ Pezzoli, S; Emsell, L; Yip, SW; Dima, D; Giannakopoulos, P; Zarei, M; Tognin, S; Arnone, D; James, A; Haller, S; Frangou, S; Goodwin, GM; McDonald, C; Kempton, MJ (January 2018). "Meta-analysis of regional white matter volume in bipolar disorder with replication in an independent sample using coordinates, T-maps, and individual MRI data". Neuroscience and Biobehavioral Reviews. 84: 162–170. doi:10.1016/j.neubiorev.2017.11.005. PMC 5771263. PMID 29162519.
- 1 2 Chen, CH; Suckling, J; Lennox, BR; Ooi, C; Bullmore, ET (February 2011). "A quantitative meta-analysis of fMRI studies in bipolar disorder". Bipolar Disorders. 13 (1): 1–15. doi:10.1111/j.1399-5618.2011.00893.x. PMID 21320248.
- ↑ Brooks III, John; Ketter, Terrence; Wang, Po (2010). "Functional Imaging Studies in Bipolar: Focus on Cerebral Metabolism and Blood Flow". In Yatham, L; Maj, M (eds.). Bipolar Disorder Clinical and Neurobiological Foundations. Wiley Blackwell.
- ↑ Blond, B; Blumberg, H. "Functional Neuroimaging Research in Bipolar". In Manji, H; Zarate, C (eds.). Behavioral Neurobiology of Bipolar Disorder and its Treatment. pp. 230–240.
- ↑ Patel, N; Nandagopal, J; Cerullo, M; Fleck, D; Adler, C; Strakowski, S; DelBello, M. "Neuroimaging Biomarkers for Bipolar Disorder Across the Lifespan". In Ritsner, M (ed.). The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes: Volume II: Neuroanatomical and Neuroimaging Endophenotypes and Biomarkers. Springer.
- ↑ Phillips, ML; Swartz, HA (August 2014). "A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research". The American Journal of Psychiatry. 171 (8): 829–43. doi:10.1176/appi.ajp.2014.13081008. PMC 4119497. PMID 24626773.
- ↑ Nusslock, R; Young, CB; Damme, KS (November 2014). "Elevated reward-related neural activation as a unique biological marker of bipolar disorder: assessment and treatment implications". Behaviour Research and Therapy. 62: 74–87. doi:10.1016/j.brat.2014.08.011. PMC 6727647. PMID 25241675.
- ↑ Wegbreit, E; Cushman, GK; Puzia, ME; Weissman, AB; Kim, KL; Laird, AR; Dickstein, DP (August 2014). "Developmental meta-analyses of the functional neural correlates of bipolar disorder". JAMA Psychiatry. 71 (8): 926–35. doi:10.1001/jamapsychiatry.2014.660. PMC 4545589. PMID 25100166.
- ↑ Hajek, T; Alda, M; Hajek, E; Ivanoff, J (December 2013). "Functional neuroanatomy of response inhibition in bipolar disorders--combined voxel based and cognitive performance meta-analysis". Journal of Psychiatric Research. 47 (12): 1955–66. doi:10.1016/j.jpsychires.2013.08.015. PMID 24070910. S2CID 35110187.
- ↑ Kupferschmidt, DA; Zakzanis, KK (30 August 2011). "Toward a functional neuroanatomical signature of bipolar disorder: quantitative evidence from the neuroimaging literature". Psychiatry Research. 193 (2): 71–9. doi:10.1016/j.pscychresns.2011.02.011. PMID 21676596. S2CID 1088195.
- ↑ Delvecchio, G; Fossati, P; Boyer, P; Brambilla, P; Falkai, P; Gruber, O; Hietala, J; Lawrie, SM; Martinot, JL; McIntosh, AM; Meisenzahl, E; Frangou, S (February 2012). "Common and distinct neural correlates of emotional processing in Bipolar Disorder and Major Depressive Disorder: a voxel-based meta-analysis of functional magnetic resonance imaging studies". European Neuropsychopharmacology. 22 (2): 100–13. doi:10.1016/j.euroneuro.2011.07.003. PMID 21820878. S2CID 2424288.
- ↑ Frangou, S (May 2014). "A systems neuroscience perspective of schizophrenia and bipolar disorder". Schizophrenia Bulletin. 40 (3): 523–31. doi:10.1093/schbul/sbu017. PMC 3984528. PMID 24609453.
- ↑ Savitz, J; Drevets, W. "Neuroimaging and Neuropathological Findings in Bipolar Disorder". In H, Manji; Zarate, C (eds.). Behavioral Neurobiology of Bipolar Disorder and its Treatment. Springer. pp. 200–208.
- ↑ Savitz, J; Drevets, W (2011). "Neuroimaging and Neuropathological Findings in Bipolar Disorder". In H, Manji; Zarate, C (eds.). Behavioral Neurobiology of Bipolar Disorder and its Treatment. Springer. pp. 208–212.
- ↑ Gigante, AD; Bond, DJ; Lafer, B; Lam, RW; Young, LT; Yatham, LN (August 2012). "Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis". Bipolar Disorders. 14 (5): 478–87. doi:10.1111/j.1399-5618.2012.01033.x. PMID 22834460. S2CID 6399247.
- ↑ Chitty, KM; Lagopoulos, J; Lee, RS; Hickie, IB; Hermens, DF (November 2013). "A systematic review and meta-analysis of proton magnetic resonance spectroscopy and mismatch negativity in bipolar disorder". European Neuropsychopharmacology. 23 (11): 1348–63. doi:10.1016/j.euroneuro.2013.07.007. PMID 23968965. S2CID 21493091.
- ↑ Kraguljac, NV; Reid, M; White, D; Jones, R; den Hollander, J; Lowman, D; Lahti, AC (2012). "Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis". Psychiatry Research. 203 (2–3): 111–25. doi:10.1016/j.pscychresns.2012.02.003. PMC 3466386. PMID 22981426.
- ↑ Monkul, ES; Yildiz, A; C Soares, J (2004). "[Magnetic resonance spectroscopy (MRS) applications in bipolar disorder]". Turk Psikiyatri Dergisi = Turkish Journal of Psychiatry. 15 (2): 138–47. PMID 15208769.
- ↑ Silverstone, PH; McGrath, BM; Kim, H (February 2005). "Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings". Bipolar Disorders. 7 (1): 1–10. doi:10.1111/j.1399-5618.2004.00174.x. PMID 15654927.
- ↑ Lyoo, Kyoon; Renshaw, Perry (2010). "Functional Magnetic Resonance Imaging, Diffusion Tensor Imaging, and Magnetic Resonance Spectroscopy in Bipolar Disorder". In Yatham, Lakshmi; Maj, Mario (eds.). Bipolar Disorder: Clinical and Neurobiological Foundations. Wiley Blackwell.
- ↑ Schür, RR; Draisma, LW; Wijnen, JP; Boks, MP; Koevoets, MG; Joëls, M; Klomp, DW; Kahn, RS; Vinkers, CH (September 2016). "Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies". Human Brain Mapping. 37 (9): 3337–52. doi:10.1002/hbm.23244. PMC 6867515. PMID 27145016.
- ↑ Savitz, J; Drevets, W (2011). "Neuroimaging and Neuropathological Findings in Bipolar Disorder". In H, Manji; Zarate, C (eds.). Behavioral Neurobiology of Bipolar Disorder and its Treatment. Springer. p. 107.
- ↑ van Enkhuizen, J; Janowsky, DS; Olivier, B; Minassian, A; Perry, W; Young, JW; Geyer, MA (15 April 2015). "The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited". European Journal of Pharmacology. 753: 114–26. doi:10.1016/j.ejphar.2014.05.063. PMC 4318788. PMID 25107282.
- 1 2 Manji, HK; Quiroz, JA; Payne, JL; Singh, J; Lopes, BP; Viegas, JS; Zarate, CA (October 2003). "The underlying neurobiology of bipolar disorder". World Psychiatry. 2 (3): 136–46. PMC 1525098. PMID 16946919.
- 1 2 Savitz, JB; Drevets, WC (April 2013). "Neuroreceptor imaging in depression". Neurobiology of Disease. 52: 49–65. doi:10.1016/j.nbd.2012.06.001. PMID 22691454.
- ↑ Savitz, J; Drevets, W (2011). "Neuroimaging and Neuropathological Findings in Bipolar Disorder". In H, Manji; Zarate, C (eds.). Behavioral Neurobiology of Bipolar Disorder and its Treatment. Springer. p. 110.
- ↑ Savitz, J; Drevets, W (2011). "Neuroimaging and Neuropathological Findings in Bipolar Disorder". In H, Manji; Zarate, C (eds.). Behavioral Neurobiology of Bipolar Disorder and its Treatment. Springer. p. 112.
- ↑ Jacobs, Barry; Müller, Christian (2009). Handbook of the behavioral neurobiology of serotonin (1st ed.). London: Elsevier. p. 329. ISBN 978-0-12-374634-4.
- 1 2 Salvadore, G; Quiroz, JA; Machado-Vieira, R; Henter, ID; Manji, HK; Zarate CA, Jr (November 2010). "The neurobiology of the switch process in bipolar disorder: a review". The Journal of Clinical Psychiatry. 71 (11): 1488–501. doi:10.4088/JCP.09r05259gre. PMC 3000635. PMID 20492846.
- ↑ Belvederi Murri, M; Prestia, D; Mondelli, V; Pariante, C; Patti, S; Olivieri, B; Arzani, C; Masotti, M; Respino, M; Antonioli, M; Vassallo, L; Serafini, G; Perna, G; Pompili, M; Amore, M (January 2016). "The HPA axis in bipolar disorder: Systematic review and meta-analysis". Psychoneuroendocrinology. 63: 327–42. doi:10.1016/j.psyneuen.2015.10.014. hdl:11392/2400889. PMID 26547798. S2CID 25771808.
- 1 2 Dinan, Timothy; Bauer, Michael (2010). "Neuroendocrinology of Bipolar Disorder". In Yatham, Lakshmi; Maj, Mario (eds.). Bipolar Disorder: Clinical and Neurobiological Foundations. Wiley-Blackwell.
- ↑ Fernandes, BS; Molendijk, ML; Köhler, CA; Soares, JC; Leite, CM; Machado-Vieira, R; Ribeiro, TL; Silva, JC; Sales, PM; Quevedo, J; Oertel-Knöchel, V; Vieta, E; González-Pinto, A; Berk, M; Carvalho, AF (30 November 2015). "Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies". BMC Medicine. 13: 289. doi:10.1186/s12916-015-0529-7. PMC 4666054. PMID 26621529.
- ↑ Escelsior, Andrea; Sterlini, Bruno; Tardito, Samuele; Altosole, Tiziana; Magioncalda, Paola; Martino, Matteo; Serafini, Gianluca; Murri, Martino Belveri; Aguglia, Andrea; Amerio, Andrea; da Silva, Beatriz Pereira; Trabucco, Alice; Fenoglio, Daniela; Filaci, Gilberto; Amore, Mario (2022-10-01). "Evidence of alterations of Beta-endorphin levels and Mu-opioid receptor gene expression in bipolar disorder". Psychiatry Research. 316 114787. doi:10.1016/j.psychres.2022.114787. ISSN 0165-1781.
- 1 2 Gawryluk, J; Young, T. "Signal Transduction Pathways in the Pathophysiology of Bipolar Disorder". In Manji, H; Zarate, C (eds.). Behavioral Neurobiology of Bipolar Disorder And its Treatment. Springer. pp. 151–152.
- 1 2 Andreazza, Ana; Feng Wang, Jun; Young, Trevor (2010). "Molecular Biology of Bipolar Disorder". In Yatham, Lakshmi; Maj, Mario (eds.). Bipolar Disorder: Clinical and Neurobiological Foundations. Wiley-Blackwell. ISBN 978-0-470-72198-8.
- ↑ Arnsten, AFT; Manji, HK (March 2008). "Mania: a rational neurobiology". Future Neurology. 3 (2): 125–131. doi:10.2217/14796708.3.2.125.
- ↑ Saxena, A; Scaini, G; Bavaresco, DV; Leite, C; Valvassoria, SS; Carvalho, AF; Quevedo, J (November 2017). "Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature". Molecular Neuropsychiatry. 3 (2): 108–124. doi:10.1159/000480349. PMC 5701269. PMID 29230399.
- ↑ Muneer, A (31 May 2017). "Wnt and GSK3 Signaling Pathways in Bipolar Disorder: Clinical and Therapeutic Implications". Clinical Psychopharmacology and Neuroscience. 15 (2): 100–114. doi:10.9758/cpn.2017.15.2.100. PMC 5426498. PMID 28449557.
- ↑ Rapoport, SI; Basselin, M; Kim, HW; Rao, JS (October 2009). "Bipolar disorder and mechanisms of action of mood stabilizers". Brain Research Reviews. 61 (2): 185–209. doi:10.1016/j.brainresrev.2009.06.003. PMC 2757443. PMID 19555719.
- ↑ Harrison, PJ; Geddes, JR; Tunbridge, EM (January 2018). "The Emerging Neurobiology of Bipolar Disorder". Trends in Neurosciences. 41 (1): 18–30. doi:10.1016/j.tins.2017.10.006. PMC 5755726. PMID 29169634.
- ↑ da Rosa, MI; Simon, C; Grande, AJ; Barichello, T; Oses, JP; Quevedo, J (December 2016). "Serum S100B in manic bipolar disorder patients: Systematic review and meta-analysis". Journal of Affective Disorders. 206: 210–215. doi:10.1016/j.jad.2016.07.030. PMID 27475892.
- ↑ Savitz, J; Drevets, W (2011). "Neuroimaging and Neuropathological Findings in Bipolar Disorder". In H, Manji; Zarate, C (eds.). Behavioral Neurobiology of Bipolar Disorder and its Treatment. Springer. p. 193.
- ↑ Young, Trevor; Cintoh, Arabah. "Understanding the Neurobiology of Bipolar Depression". In Zarate, C; Manji, H (eds.). Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis and Pharmacotherapy (Milestones in Drug Therapy) (2nd ed.). Springer.
- ↑ Savitz, J; Drevets, W (2011). "Neuroimaging and Neuropathological Findings in Bipolar Disorder". In H, Manji; Zarate, C (eds.). Behavioral Neurobiology of Bipolar Disorder and its Treatment. Springer. pp. 125–130.
- ↑ Savitz, J; Drevets, W (2011). "Neuroimaging and Neuropathological Findings in Bipolar Disorder". In H, Manji; Zarate, C (eds.). Behavioral Neurobiology of Bipolar Disorder and its Treatment. Springer. p. 143.
- ↑ Fountoulakis, KN (2012). "The possible involvement of NMDA glutamate receptor in the etiopathogenesis of bipolar disorder". Current Pharmaceutical Design. 18 (12): 1605–8. doi:10.2174/138161212799958585. PMID 22280433.
- ↑ Gigante, AD; Young, LT; Yatham, LN; Andreazza, AC; Nery, FG; Grinberg, LT; Heinsen, H; Lafer, B (September 2011). "Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis". The International Journal of Neuropsychopharmacology. 14 (8): 1075–89. doi:10.1017/S146114571000146X. PMID 21205433.
- ↑ Vawter, MP; Freed, WJ; Kleinman, JE (15 September 2000). "Neuropathology of bipolar disorder". Biological Psychiatry. 48 (6): 486–504. doi:10.1016/s0006-3223(00)00978-1. PMID 11018222. S2CID 8145510.
- ↑ Savitz, JB; Price, JL; Drevets, WC (May 2014). "Neuropathological and neuromorphometric abnormalities in bipolar disorder: view from the medial prefrontal cortical network". Neuroscience and Biobehavioral Reviews. 42: 132–47. doi:10.1016/j.neubiorev.2014.02.008. PMID 24603026. S2CID 1171487.
- ↑ Muneer, A (January 2016). "The Neurobiology of Bipolar Disorder: An Integrated Approach". Chonnam Medical Journal. 52 (1): 18–37. doi:10.4068/cmj.2016.52.1.18. PMC 4742607. PMID 26865997.
- ↑ Elhaik, E; Zandi, P (November 2015). "Dysregulation of the NF-κB pathway as a potential inducer of bipolar disorder". Journal of Psychiatric Research. 70: 18–27. doi:10.1016/j.jpsychires.2015.08.009. PMID 26424419.